Computational Drug Discovery and Design Strategies

Computational drug discovery and design strategies encompass an array of in silico methods that accelerate the identification, optimisation and validation of therapeutic candidates. Advances in structural biology, cheminformatics and machine learning have enabled the interrogation of vast chemical spaces and biological targets with unprecedented speed. Structure-based approaches leverage three-dimensional information from protein structures to predict binding modes and affinities through molecular docking and dynamic simulations. Ligand-based methods exploit known actives to derive quantitative structure–activity relationships and pharmacophore models that guide virtual screening campaigns. Integration of predictive models for absorption, distribution, metabolism, excretion and toxicity (ADMET) informs early-stage prioritisation, reducing costly late-stage failures. Emerging artificial intelligence and generative algorithms now facilitate de novo design of molecules with optimised pharmacological profiles. Combined with high-performance computing and cloud platforms, these strategies foster a more efficient, cost-effective and globally impactful paradigm in drug development.

Research from Nature Portfolio

Recent studies have introduced SwissADME, a user-friendly web tool for rapid in silico evaluation of key pharmacokinetic and physicochemical properties. It integrates robust algorithms for lipophilicity, water solubility, bioavailability radar and drug-likeness assessment, enabling screening of large compound libraries early in lead optimisation. Enhanced prediction engines support chemists in prioritising candidates with favourable ADMET profiles before synthesis, thereby streamlining decision-making and reducing resource consumption.

Computational Drug Discovery and Design Strategies publication trend

The graph below shows the total number of articles in computational drug discovery and design strategies across all publications each year (not limited to Nature Index journals).

Technical terms

ADMET: A collective term for Absorption, Distribution, Metabolism, Excretion and Toxicity properties that influence a drug’s performance in vivo.

Molecular docking: A computational technique that predicts the preferred orientation and binding affinity of a ligand within a target’s active site.

De novo design: The generation of novel chemical structures via computational algorithms based on predefined property criteria.

Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolised and excreted in a biological system.

Generative model: A machine learning framework capable of creating new molecular structures by learning patterns from training data.

Ligand: A small molecule that binds to a biological macromolecule, typically to modulate its function or activity.

References

1. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports (2017).
2. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research (2021).
3. Molecular Docking and Structure-Based Drug Design Strategies. Molecules (2015).
4. Molecular de-novo design through deep reinforcement learning. Journal of Cheminformatics (2017).